Study of ALZ Adopts BYOD Technology
Datacubed Health’s mobile platform has been selected to support studies for those at risk of Dominantly Inherited Alzheimer’s Disease, a rare form of early-onset Alzheimer’s Disease. The Linkt platform enables the collection of real-time data on sleep, diet and other biomarkers using a “bring your own device” (BYOD) study model.
Datacubed Health’s app, platform and web-based portal will be used by scientists at the Dominantly Inherited Alzheimer Network (DIAN) at the Washington University School of Medicine in Saint Louis. The DIAN research incorporates an observational study, clinical drug trials, a research registry and smaller ancillary studies.
The app and portal utilize a gamified experience with rewards for completion and compliance. Participants navigate an interactive map journey creating variable rewards such as digital gems and visual progress as they complete articles, surveys and tasks. Datacubed Health’s tools allow researchers and study coordinators to enroll participants, monitor real-time progress and compliance dashboards, manage incentives and review study data.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
